Prediction Of Poor Responders To Neoadjuvant Chemotherapy In Patients With Osteosarcoma: Additive Value Of Diffusion-Weighted Mri Including Volumetric Analysis To Standard Mri At 3t

ObjectiveTo evaluate the added value of diffusion weighted image (DWI) including volumetric analysis to standard magnetic resonance imaging (MRI) for predicting poor responders to neoadjuvant chemotherapy in patients with osteosarcoma at 3-Tesla.Methods3-Tesla Standard MRI and DWI in 17 patients were reviewed by two independent readers. Standard MRI was reviewed using a five-level-confidence score. Two-dimensional (2D) apparent diffusion coefficient (ADC) mean and 2D ADC(minimum) were measured from a single-section region of interest. An ADC histogram derived from whole-tumor volume was generated including 3D ADC(mean), 3D ADC(skewness), and 3D ADC(kurtosis). The Mann-Whitney-U test, receiver operating characteristic curve with area under the curve (AUC) analysis, and multivariate logistic regression analysis were performed.ResultsThere were 13 poor responders and 4 good responders. Statistical differences were found in posttreatment and percent change of both 2D ADC(mean) and 2D ADC(minimum), posttreatment 3D ADC(mean), and posttreatment 3D ADC(skewness) between two groups. The best predictors of poor responders were posttreatment 2D ADC(mean) and posttreatment 3D ADC(skewness). Sensitivity and specificity of the 1st model (standard MRI alone), 2nd model (standard MRI+posttreatment 2D ADC(mean)), and 3rd model (standard MRI+posttreatment 2D ADC(mean)+posttreatment 3D ADC(skewness)) were 85% and 25%, 85% and 75%, and 85% and 100% for reader 1 and 77% and 25%, 77% and 50%, and 85% and 100% for reader 2, respectively. The AUC of the 1st, 2nd, and 3rd models were 0.548, 0.798, and 0.923 for reader 1 and 0.510, 0.635, and 0.923 for reader 2, respectively.ConclusionThe addition of DWI including volumetric analysis to standard MRI improves the diagnostic accuracy for predicting poor responders to neoadjuvant chemotherapy in patients with osteosarcoma at 3-Tesla.